Current Guidelines Have Limited Applicability to Patients with Comorbid Conditions: A Systematic Analysis of Evidence-Based Guidelines by Lugtenberg, Marjolein et al.
Current Guidelines Have Limited Applicability to Patients
with Comorbid Conditions: A Systematic Analysis of
Evidence-Based Guidelines
Marjolein Lugtenberg
1,2*, Jako S. Burgers
2,3, Carolyn Clancy
4, Gert P. Westert
1,2, Eric C. Schneider
5,6,7
1Scientific Centre for Care and Welfare (Tranzo), Tilburg University, Tilburg, The Netherlands, 2Scientific Institute for Quality of Healthcare (IQ Healthcare), Radboud
University Nijmegen Medical Centre, Nijmegen, The Netherlands, 3Dutch College of General Practitioners (NHG), Utrecht, The Netherlands, 4Agency for Healthcare
Research and Quality (AHRQ), Rockville, Maryland, United States of America, 5Harvard School of Public Health, Boston, Massachusetts, United States of America, 6RAND
Corporation, Boston, Massachusetts, United States of America, 7Division of General Medicine and Primary Care, Brigham and Women’s Hospital, Boston, Massachusetts,
United States of America
Abstract
Background: Guidelines traditionally focus on the diagnosis and treatment of single diseases. As almost half of the patients
with a chronic disease have more than one disease, the applicability of guidelines may be limited. The aim of this study was
to assess the extent that guidelines address comorbidity and to assess the supporting evidence of recommendations
related to comorbidity.
Methodology/Principal Findings: We conducted a systematic analysis of evidence-based guidelines focusing on four highly
prevalent chronic conditions with a high impact on quality of life: chronic obstructive pulmonary disease, depressive
disorder, diabetes mellitus type 2, and osteoarthritis. Data were abstracted from each guideline on the extent that
comorbidity was addressed (general comments, specific recommendations), the type of comorbidity discussed (concordant,
discordant), and the supporting evidence of the comorbidity-related recommendations (level of evidence, translation of
evidence). Of the 20 guidelines, 17 (85%) addressed the issue of comorbidity and 14 (70%) provided specific
recommendations on comorbidity. In general, the guidelines included few recommendations on patients with comorbidity
(mean 3 recommendations per guideline, range 0 to 26). Of the 59 comorbidity-related recommendations provided, 46
(78%) addressed concordant comorbidities, 8 (14%) discordant comorbidities, and for 5 (8%) the type of comorbidity was
not specified. The strength of the supporting evidence was moderate for 25% (15/59) and low for 37% (22/59) of the
recommendations. In addition, for 73% (43/59) of the recommendations the evidence was not adequately translated into
the guidelines.
Conclusions/Significance: Our study showed that the applicability of current evidence-based guidelines to patients with
comorbid conditions is limited. Most guidelines do not provide explicit guidance on treatment of patients with comorbidity,
particularly for discordant combinations. Guidelines should be more explicit about the applicability of their
recommendations to patients with comorbidity. Future clinical trials should also include patients with the most prevalent
combinations of chronic conditions.
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Introduction
Traditionally, medical care is focused on the prevention,
diagnosis and treatment of single diseases [1]. Most research
studies focus on the effectiveness of disease-specific interventions
and patients with comorbidity or complex problems are often
excluded from clinical trials [2,3]. In clinical practice, physicians
are encouraged to adhere to evidence-based clinical practice
guidelines (CPGs), as these are regarded as important tools for
quality improvement [4]. In line with both clinical practice and
research traditions, most CPGs are disease-oriented documents
focusing on the diagnosis and management of single diseases [5].
The emphasis of CPGs on single diseases may be problematic.
Almost half of patients with chronic diseases have more than one
disease [6,7]. Managing multiple conditions is more complex than
managing single diseases and clinicians may find it challenging to
provide optimal care for patients with multiple conditions [8–10].
Particularly when conditions are discordant, i.e. if they are not
directly related in either their pathogenesis or management and do
not share an underlying predisposing factor, patients are more
likely to report conflicting instructions and problems with
coordination of care [11–13].
To the extent that CPGs focus on single diseases, they may offer
insufficient guidance to physicians about care for patients with
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comorbidity may pose an important barrier to guideline adherence
among physicians [14,15]. Moreover, adhering to single disease
CPGs in caring for patients with multiple conditions may
adversely affect patient safety, if recommended treatments for
one condition conflict with those for another condition [16].
Although prior studies suggest that physicians may find it
challenging to provide care to patients with comorbidity, there are
few systematic assessments of the comorbidity-related content of
CPGs, and in particular the quality of the evidence that supports
that content. The aim of this study was to explore the applicability
of CPGs to patients with comorbidity by assessing the extent to
which CPGs on high-prevalence chronic conditions address
comorbidity and by assessing the quality of the evidence cited in
support of recommendations related to comorbidity.
Methods
Data sources
Two publicly-available international databases, the National
Guideline Clearinghouse (NGC) and the Guidelines International
Network Library (G-I-N),were used to select the guidelines.
Study selection
Selection of chronic conditions. In selecting the conditions,
we focused on highly prevalent chronic diseases that have a high
impact on quality of life. Both major depressive disorder [17,18]
and diabetes mellitus type 2 [19,20] are highly prevalent and have
been found to have a high impact on quality of life, particularly in
combination [17,21]. We also included chronic obstructive
pulmonary disease (COPD) and osteoarthritis, as pain and
dyspnea may have a considerable impact on quality of life as well.
Selection of clinical practice guidelines
Guidelines were included if they:
N included a set of recommendations with an explicit link to their
supporting evidence;
N were published in 2005 or later;
N addressed the treatment or management of the selected
conditions;
N were published in English;
N were accessible in the public domain.
CPGs were excluded if they focused on a specific subgroup of
patients (e.g. pregnant women, children, adolescents, homeless
people).
Data extraction
One of the investigators (ML) abstracted data from the selected
CPGs and the abstraction process was checked by a second
investigator (JB). Any disagreement was resolved by discussion.
General data were retrieved from the CPGs, and more detailed
information was collected on the specific recommendations
addressing comorbidity and their supporting evidence:
Guideline
N General characteristics of the guideline: title; organization;
country; target group; year of publication; number of pages
and references; number of treatment recommendations.
N Characteristics of the guideline related to comorbidity: issue of
comorbidity addressed (prevalence data, screening/diagnosing
for comorbidity; considering comorbidity in treatment);
discussion of patient-centered aspects (such as goals and
burden of treatment, incorporating patient preferences),
inclusion of specific comorbidity-related treatment recommen-
dations (number and proportion). A recommendation was
defined as a statement whose apparent intent is to provide
guidance about the advisability of a clinical action [22].
Contra-indications for medication or surgery were not
considered as specific comorbidity-related recommendations,
if no alternative treatments were provided.
Recommendation
N Type of recommendation: type of treatment addressed (general
treatment, drug therapy, life-style advice, surgery, other);
inclusion of patient-centered aspects.
N Number of comorbid conditions addressed;
N Type of comorbidity addressed: concordant or discordant.
Concordant conditions were defined as representing the same
overall pathophysiological risk profile and being more likely to
be the focus of the same disease and self management plan
[12]. Discordant treatments are not directly related in either
their pathogenesis or management. For each of the included
conditions the authors developed a scheme of concordant and
discordant comorbidities (File S1). For diabetes, we did not
consider cardiovascular risk factors such as hypertension and
hyperlipidemia as concordant conditions but as part of the
disease, because adequate management of diabetes is cardio-
vascular risk management including monitoring blood pressure
and lipids.
Evidence
N Link with underlying evidence described; (yes, no)
N Number of underlying studies;
N Level of evidence of underlying studies: high, moderate, low,
not available. As grading systems differ per guideline, we
considered the highest level of evidence as high, the lowest
level as low, and intermediate levels as moderate.
N Translation of evidence: good, moderate or poor/unclear. Our
judgment was based on the directness of the evidence and on
whether the strengths and limitations of the evidence were
discussed in the guideline. The translation was graded as:
‘good’ if the supporting evidence of the studies focused (at least
partly) on the comorbidity part of the recommendation and
the strengths and limitations of the supporting evidence were
discussed in the guideline; as ‘moderate’ if either the
supporting evidence of the studies focused (at least partly) on
the comorbidity part of the recommendation or the strengths
and limitations of the supporting evidence were discussed in
the guideline; and as ‘poor or unclear’ if neither the supporting
evidence of the studies focused on the comorbidity part of the
recommendation nor were the strengths and limitations of the
supporting evidence discussed in the guideline.
Results
A total of 20 CPGs met our inclusion criteria, having been
published in English and in the public domain since 2005 (Table 1).
Six of the CPGs addressed COPD, four addressed major
depressive disorder, seven addressed diabetes mellitus type 2 and
three addressed osteoarthritis.
Eight CPGs were retrieved from the G-I-N database, six from
the NGC database and six were available in both databases. The
Guidelines and Patients with Comorbid Conditions
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(n=7). Nine CPGs were produced by governmental agencies; five
by professional societies and six by other types of organizations.
The CPGs were predominantly developed in 2008 (7/20) and in
2007 (5/20).
Applicability of guidelines to patients with comorbidity
Of the 20 guidelines, 17 (85%) addressed the issue of
comorbidity (Table 2). Eight guidelines (40%) provided comor-
bidity prevalence data, 16 guidelines (80%) recommended
screening for comorbid conditions and 17 guidelines (85%)
Table 1. Basic characteristics of selected guidelines (N=20).
Title of guideline
Organization that
developed guideline Country Year
No. of
pages
No. of
references
COPD
1. Chronic obstructive pulmonary disease Singapore Ministry of Health Singapore 2006 84 155
2. Diagnosis and management of Chronic obstructive
pulmonary disease (COPD)
Institute for Clinical Systems
Improvement (ICSI)
USA 2009 51 97
3. Diagnosis and management of stable chronic
obstructive pulmonary disease: a clinical practice
guideline from the American College of Physicians
American College of Physicians USA 2007 6 54
4. Global strategy for the diagnosis,
management, and prevention of chronic
obstructive pulmonary disease
Global Initiative for Chronic Obstructive
Lung Disease - Disease Specific Society
(WHO), National Heart, Lung, and Blood
Institute (U.S.)
Several countries 2008 94 435
5. Australian Lung Foundation & The Thoracic
Society of Australia and New Zealand - The COPD-X
Plan: Australian and New Zealand Guidelines for the
management of Chronic Obstructive Pulmonary
Disease 2006
New Zealand Guidelines Group (NZGG) New Zealand 2006 66 243
6. Canadian Thoracic Society Recommendations for
Management of Chronic Obstructive
Pulmonary Disease, CTS (CA)
Canadian Thoracic Society Canada 2007 28 366
DEPPRESIVE DISORDER (MAJOR)
7. Major depression in adults in primary care Institute for Clinical Systems
Improvement (ICSI)
USA 2008 84 244
8. Identification of common mental disorders and
management of depression in primary care
New Zealand Guidelines
Group (NZGG)
New Zealand 2008 188 580
9. Using Second-Generation Antidepressants to
Treat Depressive Disorders: A Clinical Practice
Guideline from the American College of Physicians
American College
of Physicians (ACP)
USA 2008 10 100
10. A. Depression: the treatment and
management of depression in adults (update) (CG90)
National Institute for Health and
Clinical Excellence (NICE)
United Kingdom 2009 64 (FG=585)0 (FG.1000)
DIABETES MELLITUS TYPE 2
11. American Association of Clinical
Endocrinologists medical guidelines for clinical
practice for the management of diabetes mellitus
American Association of Clinical
Endocrinologists, American
College of Endocrinology
USA 2007 68 564
12. Diabetes mellitus Singapore Ministry of Health Singapore 2006 161 260
13. Diagnosis and management of type 2
diabetes mellitus in adults
Institute for Clinical Systems
Improvement (ICSI)
USA 2008 89 126
14. Guidelines on diabetes, pre-diabetes, and
cardiovascular diseases
European Society of Cardiology Several European
countries
2007 72 711
15. Standards of medical care in diabetes American Diabetes Association USA 2008 43 332
16. National evidence-based guidelines for
type 2 diabetes mellitus (Part 1, 3, 4, 5 & 7)
National Health and Medical
Research Council (NHMRC)
Australia 2005 928 .1000
17. Type 2 diabetes - the management of type 2
diabetes (partial update)+newer agents (CG87)
National Institute for Health and
Clinical Excellence (NICE)
United Kingdom 2009 151
(FG=259)
0 (FG=414)
OSTEOARTHRITIS
18. Osteoarthritis of the knees Singapore Ministry of Health Singapore 2007 51 91
19. The care and management of
osteoarthritis in adults
National Institute for Health and
Clinical Excellence (NICE)
United Kingdom 2008 22 (FG=316)0 (FG=386)
20. Ottawa Panel evidence-based clinical practice
guidelines for therapeutic exercises and
manual therapy in the management of osteoarthritis
Ottawa Panel Canada 2005 65 178
FG=Full guideline.
doi:10.1371/journal.pone.0025987.t001
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on depressive disorder and diabetes mellitus type 2 (100%) more
often addressed the issue of comorbidity compared to the
guidelines on COPD (83%) and osteoarthritis (33%).
Fourteen (70%) guidelines provided specific treatment recom-
mendation for patients with comorbid conditions. The number of
recommendations varied from 1 to 26 per guideline, with an
average of 3 per guideline. The guidelines on COPD and
osteoarthritis provided the fewest numbers of recommendations
(0.7 per guideline), whereas the guidelines on diabetes mellitus
type 2 included an average of 6.3 comorbidity-related recommen-
dations.
The 20 guidelines provided a total of 59 comorbidity-related
treatment recommendations (Table 3). Seventy-eight percent (46/
59) of these recommendations addressed concordant comorbidi-
ties. Most of the diabetes mellitus type 2 guideline recommenda-
tions addressed concordant comorbidities such as coronary artery
disease and heart failure. Relative to the other guidelines, the
guidelines on depressive disorder included the largest proportion
(33%) of recommendations on discordant comorbidities (such as
cardiovascular disease). More than 90% of the recommendations
were related to one comorbid condition; 10% focused on
comorbidities in general and none of the recommendations
specified the management of patients with more than one
comorbid condition.
Fifty-four percent of the comorbidity-related recommendations
concerned drug therapy (32/59); 25% related to other types of
treatment such as psychotherapy or oxygen therapy (15/59). Few
recommendations focused on surgery (10%; 6/59) and on life-style
advice (3%; 2/59). Twelve percent of the recommendations (7/59)
provided specific guidance on patient-centered aspects such as
patient preferences, burden of disease and priority setting.
The link between guideline recommendation statements and the
supporting evidence was described for 97% of the recommenda-
tions (57/59). The number of underlying studies varied between 1
and 12 per recommendation. The level of evidence of the studies
was generally weak: 37% of the recommendations (22/59) had a
‘low’ level of evidence; for 25% of the recommendations (15/59)
the level of evidence was described as ‘moderate’ (Table 4 and 5).
For 73% of the recommendations (43/59), the evidence
underlying the studies was not adequately translated into the
guideline with 48% (28/59) graded as ‘moderate’ and 25% (15/
59) as ‘poor or unclear’ (Table 4 and 5). Translation of evidence
was rated more frequently as ‘good’ for guidelines on diabetes
mellitus type 2 (32% [14/44]) than those on depression (22%
[2/9]); none of the guidelines on COPD and osteoarthritis
received a ‘good’ rating for evidence translation (Table 4).
Discussion
Patients with multiple comorbid conditions are very frequently
encountered in clinical practice. However, our results suggest that
evidence-based guidelines on four relatively prevalent chronic
diseases may have limited applicability to patients with comorbid
conditions. Most of these guidelines do not provide explicit
guidance on treatment of patients with specific combinations of
diseases. If comorbidity is addressed in the guidelines, it is often
discussed in general; few specific treatment recommendations for
patients with comorbid conditions are provided, particularly for
discordant combinations. Moreover, the evidence supporting the
available comorbidity-related recommendations was generally
limited, had moderate to poor quality, and was often not
adequately translated into the guidelines.
Among the guidelines in our study that included specific
comorbidity-related recommendations, these recommendations
were more likely to focus on concordant comorbidities with
related treatment plans. We also found that none of the
comorbidity-related recommendations specified the preferred
action for patients with more than one concurrent condition.
These results are consistent with previous American [16] and
Australian [23] studies showing that guidelines pay little attention
to patients with discordant comorbidities and to patients with
multiple chronic conditions. This lack of attention contributes to
limiting the applicability of single disease guidelines on patients
with chronic diseases as almost one third of them have three or
more conditions [24].
An important finding of our study is the limited evidence base
that supports comorbidity-related recommendations. If specific
recommendations for patients with comorbidity are provided, they
are often based on limited evidence that is of moderate or poor
quality. In addition, the supporting evidence rarely focuses directly
on the groups of patients with comorbid conditions. Furthermore,
the limitations of this evidence are not usually described in the
guidelines. The failure to describe limitations of evidence in a
guideline could give clinicians misplaced confidence in guideline
recommendations.
Consistent with previous studies, our findings indicate that the
evidence base for patients with multiple chronic conditions is
limited [2,3]. The lack of evidence specific to comorbid conditions
may explain the limited attention to comorbidity in the guidelines
we studied. If future clinical trials included patients with comorbid
Table 2. Characteristics of guidelines in terms of addressing comorbidity (N=20).
Guidelines COPD (N=6) DEP (N=4) DM II (N=7) OA (N=3) TOTAL (N=20)
N%N% N% N%N%
Issue of comorbidity addressed 5 8 34 1 0 07 1 0 01 3 31 78 5
Provision of comorbidity prevalence data 3 50 2 50 2 29 1 33 8 40
Screening/diagnosing for comorbidity 5 83 3 75 7 100 1 33 16 80
Considering comorbidity in treatment 5 83 4 100 7 100 1 33 17 85
Inclusion of patient centered aspects 4 67 3 75 4 57 1 33 12 60
Includes specific comorbidity-related treatment
recommendation(s)
3 5 04 1 0 06 8 6 1 3 31 47 0
Mean number of recommendations per guideline (range) 0.7 (0–2) 2.3 (1–4) 6.3 (0–26) 0.7 (0–2) 3.0 (0–26)
COPD=Chronic Obstructive Pulmonary Disease; DEP=Major depressive disorder; DM II=Diabetes Mellitus type 2; OA=Osteoarthritis.
doi:10.1371/journal.pone.0025987.t002
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and report the results, this would provide the evidence base that
clinical guideline developers need [16,25].
In light of the general absence of research evidence on patients
with multiple conditions, guidelines should be more explicit about
the applicability of their recommendations to patients with the
most prevalent comorbid conditions and discuss the quality and
directness of the evidence for these patients. This explicit approach
should replace the implicit assumption that guideline recommen-
dations are applicable to patients with comorbid conditions unless
conflicting evidence is available [26,27].
Our findings indicate that no systematic approach is used by
guideline development groups for addressing comorbidity in
guidelines. Compared to the guidelines on COPD, depressive
disorder, and osteoarthritis, the guidelines on diabetes mellitus
type 2 had better reporting of issues of comorbidity. Even for
guidelines on the same condition, we found large variation
between guidelines in the approach to addressing comorbidity.
Table 3. Characteristics of comorbidity-related treatment recommendations (N=59).
Comorbidity-related treatment
recommendations COPD (N=4) DEP (N=9) DM II (N=44) OA (N=2) TOTAL (N=59)
NNN NN %
Type of comorbidity addressed
concordant comorbidity 3 5 38 0 46 78
discordant comorbidity 1 3 4 0 8 14
not specified 0 1 2 2 5 8
Nr of comorbid conditions addressed
one comorbid condition 4 8 42 0 54 92
multiple comorbidities 0 0 0 0 0 0
not specified 0 1 2 2 5 8
Type of recommendation
general treatment 0 3 1 0 4 7
drug therapy 1 4 27 0 32 54
life-style advice 0 0 1 1 2 3
surgery 0 0 5 1 6 10
other* 3 2 10 0 15 25
Includes patient centered aspects 0 3 4 0 7 12
COPD=Chronic Obstructive Pulmonary Disease; DEP=Major depressive disorder; DM II=Diabetes Mellitus type 2; OA=Osteoarthritis.
*The category ‘other’ includes: psychological interventions, oxygen therapy, referral, assessment before flying, target levels, risk stratification.
doi:10.1371/journal.pone.0025987.t003
Table 4. Evidence-base of comorbidity-related treatment recommendations (N=59).
Comorbidity-related treatment recommendations COPD (N=4) DEP (N=9) DM II (N=44) OA (N=2) TOTAL (N=59)
NNN NN %
Number of underlying studies
0 or unclear 1 1 7 1 10 17
1–2 3 4 12 0 19 32
3–4 0 3 11 0 14 24
.40 1 1 4 1 1 6 2 7
Level of evidence of the studies
high 2 0 14 0 16 27
moderate 1 2 12 0 15 25
low 1 5 16 0 22 37
N.A. 0 2 2 2 6 10
Translation of evidence
good 0 2 14 0 16 27
moderate 3 3 22 0 28 48
poor or unclear 1 4 8 2 15 25
COPD=Chronic Obstructive Pulmonary Disease; DEP=Major depressive disorder; DM II=Diabetes Mellitus type 2; OA=Osteoarthritis.
doi:10.1371/journal.pone.0025987.t004
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tion, evidence). A previous study comparing diabetes guidelines
from different countries, also found much variation in the
supporting evidence, whereas the recommendations were similar
[28]. It would be helpful to develop guidance, as part of a
handbook or manual for guideline developers [29,30] to facilitate
and support this process and to create more uniformity. In
addition, targeting educational activities to professional societies
that do not yet incorporate comorbidity to a large extent in their
guidelines might be useful.
The main strength of our study is that we systematically assessed
the content of an international sample of evidence-based national and
international guidelines in terms of addressing comorbidity. The
guidelines included in our study are among the best in the clinical
areas of interest and were produced by prominent governmental
agencies or professional organizations. Furthermore, by simulta-
neously assessing the underlying evidence of the comorbidity-related
recommendations, we were able to determine whether guidance was
provided on treatment of patients with comorbid conditions and also
to what extent this guidance was based on high-quality evidence.
Our study has several limitations. First, a limited number of
chronic conditions were included in our study. Inclusion of a
different set of chronic conditions could have yielded different
results. However, we do not expect guidelines on other diseases to
be more applicable to patients with multiple conditions than those
for the included common conditions. Second, the number of
selected guidelines varied between the conditions, with an
overrepresentation of diabetes guidelines. This reflects the available
number of high-quality guidelines on the selected diseases in the
databases. Third, we did not assess all available comorbidity-related
evidence for the included chronic conditions, but only the evidence
that was described in the guidelines. A systematic search for
evidence would be necessary to determine whether the guideline
recommendations are based on the best available evidence. Future
research on the selected conditions could be useful to draw firm
conclusions on the availability of evidence for patients with multiple
conditions, complementing the findings of our study.
Among a selected set of high-quality current evidence-based
guidelines on prevalent chronic diseases, there is limited guidance
on treatment of patients with comorbid conditions. Although the
issue of comorbidity is recognized by guidelines, very few specific
recommendations are provided and these are generally based on
limited evidence of low or moderate quality. The supporting
evidence often does not focus directly on groups of patients with
Table 5. Examples of comorbidity-related treatment recommendations with different levels of supporting evidence.
Example of recommendation with moderate level of evidence and good translation of evidence
‘‘Diabetic patients with acute myocardial infarction benefit from a tight glucometabolic control. This may be accomplished by different treatment strategies’’
Level of evidence: MODERATE (Class IIa; Level B)
Translation of evidence: GOOD
‘‘Metabolic support and control: There are several reasons why intensive metabolic control during an acute myocardial infarction should be of benefit [several studies
are described ….]. Based on present knowledge, there is reasonable evidence to initiate glucose control by means of insulin infusion in diabetic patients who are
admitted for AMIs with significantly elevated blood glucose levels in order to reach normoglycaemia as soon as possible. Patients admitted with relatively normal
glucose levels may be handled with oral glucose-lowering agents. In the follow-up, both epidemiological data and recent trials support that continued strict glucose
control is beneficial. The therapeutic regime to accomplish this goal may include diet, life styles strategies, oral agents, and insulin (see also section on life style and
comprehensive management). Since there is no definite answer to which pharmacological treatment is the best choice, the final decision can be based on decisions by
the physician-in-charge in collaboration with the patient. Most importantly, the effect on long-term glucose control has to be followed and the levels should be
targeted to be as normal as possible. Several outcome studies with novel agents or regimens are ongoing and will report in the near future.’’
Comment: Several studies are discussed directly targeting the group of diabetic patients with AMI. The strengths and limitations of the available evidence are clearly
discussed and taken into consideration in making the final recommendation.
Example of recommendation with high level of evidence and moderate translation
‘‘Prevent or treat osteoporosis (in patients with COPD)’’
Level of evidence: HIGH (A)
Translation of evidence: MODERATE
‘‘Intervention should be targeted at men and women who are taking more than 15 mg daily of prednisolone or who have several risk factors for osteoporosis and
whose BMD is ,1.5 standard deviations below the young adult mean (Ref 88). Oral bisphosphonates, particularly risedronate, have been shown to be effective in
preventing and treating bone loss in men and women taking corticosteroids (Ref 88, 219). However, most patients in these studies did not have respiratory disease.
Selecting patients with COPD who may be at increased risk of osteoporosis is most appropriately done on the basis of conventional risk factors. Further refining of
clinical predictors and more evidence for the cost effectiveness of such programs still needs to be resolved before recommendations on a screening strategy in patients
with COPD can be made. For more information on prevention and treatment of osteoporosis, see the current Australian guidelines.’’
Comment: Several studies and their limitations are described, but the studies are not directly focused on patients with respiratory diseases.
Example of recommendation with low level of evidence and good translation
‘‘Treat depressed cardiac patients……….’’
Level of evidence: LOW (Consensus statement)
Translation of evidence: GOOD
‘‘As yet there are no data to support the hypothesis that antidepressant treatment improves cardiac morbidity and mortality (Jiang, 2005 [R]). Nevertheless, consensus
opinion is to treat depressed cardiac patients with a safe drug rather than watchful waiting since they would benefit from symptomatic relief of their depressive
symptoms and there is a potential improvement in their cardiovascular risk profile (Ballenger, 2001 [R]).’’
Comment: The evidence (Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on depression, anxiety, and cardiovascular disease. J Clin Psychiatry 2001)
directly applies to the group of comorbid patients. Moreover, they discuss the strengths and limitations of the evidence and take these into account in formulating the
recommendation.
doi:10.1371/journal.pone.0025987.t005
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describe the limitations of the evidence. Given the increasing
prevalence of patients with multiple chronic diseases, guidelines
should at least be explicit and transparent about the applicability
of their recommendations to populations of patients with the most
common combination of diseases. A guide for guideline developers
could facilitate a systematic and uniform approach.
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